RSV Surge: Bigger, Earlier, and Older Than Previous Seasonal Outbreaks
Although this year’s ultra-high rates of RSV hospitalizations have recently fallen, certain features of this season’s outbreak set it apart from those of previous years.
Although this year’s ultra-high rates of RSV hospitalizations have recently fallen, certain features of this season’s outbreak set it apart from those of previous years.
The combined vaccine is intended to simplify immunization practices against 2 severe respiratory diseases caused by evolving viruses that require vaccine adaptation.
Toolkit provides guidance on the COVID-19 bivalent booster and oral antiviral therapeutics.
NFID survey show beliefs about influenza and pneumococcal disease, as well as attitudes and practices around vaccination, including the impacts of the COVID-19 pandemic.
The quadrivalent modRNA influenza vaccine candidate uses mRNA technology, which requires only the genetic sequence of the virus.
In general, routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications and should be completed by the end of October.
The expanded approval was based on data from two phase 3 studies, miniSTONE-2 and BLOCKSTONE.
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
The test is the first non-prescription multi-analyte COVID-19 test that allows individuals to test nasal swab samples self-collected at home.
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.